230 related articles for article (PubMed ID: 31163446)
1. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Kang HL; Zhao Q; Yang SL; Duan W
Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
[TBL] [Abstract][Full Text] [Related]
2. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia.
Wang Y; Miao JW; Wang T; Wang Y; Wu YM; Kong WM; Su L; Duan W
J Chemother; 2016 Apr; 28(2):135-9. PubMed ID: 27105436
[TBL] [Abstract][Full Text] [Related]
3. Direct comparisons of efficacy and safety between actinomycin-D and methotrexate in women with low-risk gestational trophoblastic neoplasia: a meta-analysis of randomized and high-quality non-randomized studies.
Hao J; Zhou W; Zhang M; Yu H; Zhang T; An R; Xue Y
BMC Cancer; 2021 Oct; 21(1):1122. PubMed ID: 34663255
[TBL] [Abstract][Full Text] [Related]
4. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
[TBL] [Abstract][Full Text] [Related]
5. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients.
Hidayat YM; Darmadi A E; Rachmayati S; Kusumah WP; Djuwantono T; Pramatirta AY; Suardi D
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3325-3329. PubMed ID: 33247691
[TBL] [Abstract][Full Text] [Related]
9. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
[TBL] [Abstract][Full Text] [Related]
10. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
[TBL] [Abstract][Full Text] [Related]
12. The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy.
Wu X; Qin J; Shen T; Fei W; Chen L; Xie X; Lu W
J Gynecol Oncol; 2020 Jul; 31(4):e36. PubMed ID: 32026657
[TBL] [Abstract][Full Text] [Related]
13. Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis.
Hoskins PJ; Le N; Kumar A; Pina A; Sabourin JN; Kim H; Osborne RJ
Gynecol Oncol; 2020 May; 157(2):367-371. PubMed ID: 32143915
[TBL] [Abstract][Full Text] [Related]
14. Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial.
Yarandi F; Mousavi A; Abbaslu F; Aminimoghaddam S; Nekuie S; Adabi K; Hanjani P
Int J Gynecol Cancer; 2016 Jun; 26(5):971-6. PubMed ID: 27101581
[TBL] [Abstract][Full Text] [Related]
15. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial.
Lertkhachonsuk AA; Israngura N; Wilailak S; Tangtrakul S
Int J Gynecol Cancer; 2009 Jul; 19(5):985-8. PubMed ID: 19574798
[TBL] [Abstract][Full Text] [Related]
16. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
[TBL] [Abstract][Full Text] [Related]
17. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
18. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
[TBL] [Abstract][Full Text] [Related]
19. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia.
Baptista AM; Belfort P
Int J Gynaecol Obstet; 2012 Oct; 119(1):35-8. PubMed ID: 22877838
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of women diagnosed and treated for low-risk gestational trophoblastic neoplasia at the Queensland Trophoblast Centre (QTC).
Verhoef L; Baartz D; Morrison S; Sanday K; Garrett AJ
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):458-463. PubMed ID: 28345753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]